Posts by camerontucker
T Cell Activation in Cell Therapy: Why T Cell Activation Fails Without the Right Starting Material
Introduction T cell activation is a foundational step in cell and gene therapy workflows, particularly in CAR T and other adoptive cell therapies. While much attention is placed on genetic engineering and manufacturing scale, activation is where functional outcomes begin to take shape. When done correctly, it enables strong expansion, optimal phenotypes, and durable responses.…
For More InformationWhy CGT Global Is Positioned to Support the Next Wave of Cell and Gene Therapies
Cell and gene therapy companies rely on several critical pieces of infrastructure to move therapies from development to clinical trials and ultimately to patient treatment. These include reliable sources of GMP compatible starting material, clinical trial support for complex cell therapy workflows, and hospitals capable of administering advanced therapies. Without these components in place, even…
For More InformationBulk CD34+ Isolation from Mobilized Leukopaks: GCSF vs GCSF + PLX vs PLX
Bulk CD34+ isolation is critical for stem cell therapy development, gene editing workflows, and advanced cell therapy research. When programs require large scale CD34+ recovery, the mobilization strategy used prior to leukapheresis directly impacts yield potential, scheduling timelines, and operational efficiency. Understanding the differences between GCSF mobilization, GCSF + PLX mobilization, and PLX only mobilization…
For More InformationB Cell CAR T in Autoimmune Disease Breaks for Predictable Operational Reasons
B Cell CAR T in Autoimmune Disease Breaks for Predictable Operational Reasons B cell directed CAR T programs in autoimmune disease rarely fail because of the cell. They stall because operational assumptions borrowed from oncology do not hold once real patients and real timelines enter the picture. Teams often discover this late, usually after their…
For More InformationBlood Types Explained
What your blood type means and why it matters for donation and research Learn how ABO and Rh blood types work, how common each type is, and why donors are essential for lifesaving care and medical research. CGT Global donors are compensated from $25 and up to $1,000 for your time and effort depending on…
For More InformationFrom Donor Recall to Data Integrity: The Operational Backbone of Ex Vivo Cell Therapy
By Eliona Kola, Process Development Scientist “Hey Sophie, will the lab receive the leukopak from the recall donor tomorrow for the CD3⁺ isolations?” That’s a question we ask our Director of Logistics Operations who also leads our Donor Scheduling Department more often than not. Coordinating around a donor’s availability can be challenging for any team,…
For More InformationEverything CGT Global Offers: Starting Materials, Isolated Cells, and Clinical Grade Supply
1. Leukopaks (RUO, Mobilized, Clinical, and GMP Aligned) Leukopaks remain one of the most common upstream inputs for immune cell workflows. We support formats that match how cell therapy teams actually operate. RUO leukopaks Fresh and cryopreserved options for discovery, preclinical, and process development. Mobilized leukopaks Mobilized options for programs requiring higher progenitor content or…
For More InformationCryopreserved Leukopak Viability and Supplier Selection
What to Expect Post Thaw and How to Choose a GMP Partner Cryopreserved leukopaks are getting adopted fast for one simple reason. Fresh starting material creates supply chain risk. Leukopak deliveries can be late, arrive outside temperature requirements, or miss a critical manufacturing window entirely. When that happens, teams do not just lose a leukopak.…
For More InformationGMP Leukopak Partner Guide for Clinical Development
Plus a Fresh vs Cryopreserved Decision Guide for Allogeneic Programs If you are building a cell therapy program, your starting material is not a minor detail. It is one of the biggest drivers of downstream consistency, cost, and timeline risk. That is why the GMP leukopak has become a cornerstone input for teams moving from…
For More InformationAdvancing CAR NK Therapy: Why Leukopak Quality and Donor Characterization Matter
CAR NK therapy is gaining traction as a next wave cell therapy platform. Compared to CAR T, CAR NK programs offer the potential for allogeneic manufacturing, improved safety profiles, and scalable off the shelf products. But CAR NK workflows are less forgiving when it comes to starting material. NK cells are more sensitive to collection…
For More Information